approves

The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment

You don't have permission to access "http://www.medpagetoday.com/neurology/alzheimersdisease/122171" on this server. Reference #18.9177d917.1784037745.89a337f https://errors.edgesuite.net/18.9177d917.1784037745.89a337f

You don't have permission to access "http://www.medpagetoday.com/pulmonology/asthma/120159" on this server. Reference #18.520c3417.1772654550.22f2d66d https://errors.edgesuite.net/18.520c3417.1772654550.22f2d66d

Minister in the Presidency Jackson Mthembu delivering a post-Cabinet briefing on Thursday. All executives in government will head back to school through training programmes, Cabinet has decided.Cabinet met on Wednesday to discuss various issues, including corruption surrounding the procurement of PPE.It also postponed the hosting of the 2020 International Maritime Organisation and World Maritime Day event.Cabinet…

The IMF has agreed to extend a $4.3 billion loan to help SA's efforts to fight the Covid-19 pandemic.This follows months of engagements between Treasury and the IMF's management to iron out engagement terms. The New Development Bank and African Development Bank have also both approved Covid-19 relief loans for SA.The International Monetary Fund's executive board…